Erika Hamilton, MD

Trials

Studies that name Erika Hamilton, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:13 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05748834 · Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

  SCRI Development Innovations, LLC · recruiting · Breast Cancer · study chair
• Ph1
  NCT04991480 · A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

  Artios Pharma Ltd · completed · Advanced Cancer, Metastatic Cancer, Breast Cancer · study chair
• Ph2
  NCT04699630 · A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

  SCRI Development Innovations, LLC · completed · Metastatic Breast Cancer, Locally Advanced Breast Cancer · study chair
• Ph1/Ph2
  NCT04042116 · A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

  Clovis Oncology, Inc. · suspended · Advanced Solid Tumor, Gynecologic Cancer · principal investigator
• N/A
  NCT02436772 · Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC

  SCRI Development Innovations, LLC · completed · Metastatic Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.